Innoviva, Inc.
Financials
Valuation Metrics
Innoviva, Inc.'s Market Cap is $1.53B. At end of 2025 it was $1.50B. Ranked #2177 of 3,116 in US market (top 70%), #855 of 1,472 on NASDAQ (top 58%), #159 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.53B | US#2,177/3,116 Sec#159/265 |
| Revenue | $443M | US#2,289/3,116 Sec#82/265 |
| Net Income | $357M | US#1,004/3,116 Sec#33/265 |
| Total Assets | $1.70B | US#2,184/3,116 Sec#63/265 |
| Net Assets | $1.23B | US#1,623/3,116 Sec#53/265 |
| Employees | 159 | US#2,522/3,116 Sec#141/265 |
| Value | ||
| P/E | 4.29x | US#42/3,116 Sec#3/265 |
| P/B | 1.24x | US#654/3,116 Sec#29/265 |
| PEG | 0.01x | US#15/3,116 Sec#2/265 |
| P/S | 3.46x | US#1,894/3,116 Sec#59/265 |
| EV/EBITDA | 1.50x | US#12/3,116 Sec#2/265 |
| FCF Yield | 12.28% | US#404/3,116 Sec#16/265 |
| Profitability | ||
| ROE | 28.97% | US#316/3,116 Sec#19/265 |
| ROA | 20.98% | US#98/3,116 Sec#15/265 |
| Op. Margin | 36.66% | US#356/3,116 Sec#21/265 |
| Revenue Growth | 19.77% | US#694/3,116 Sec#74/265 |
| Earnings Growth | 824.31% | US#42/3,116 Sec#3/265 |
| Financial Health | ||
| Debt Ratio | 38.07% | US#433/3,116 Sec#123/265 |
| Total Debt | $270M | US#2,126/3,116 Sec#84/265 |
| FCF | $188M | US#1,418/3,116 Sec#47/265 |
| Cash | $570M | US#983/3,116 Sec#52/265 |
| Current Ratio | 16.01x | US#152/3,116 Sec#44/265 |
| Net Debt/EBITDA | -0.37x | US#440/3,116 Sec#26/265 |
| Dividend | ||
| Div. Growth | -87.50% | US—/3,116 Sec—/265 |
| Performance | ||
| 1Y Return | 18.27% | US#1,142/3,116 Sec#111/265 |
| 1M Return | 0.09% | US#1,756/3,116 Sec#118/265 |
| From 52W High | -15.59% | US#1,255/3,116 Sec#68/265 |
| 1Y MDD | -16.50% | US#381/3,116 Sec#10/265 |
| Trading | ||
| Volume | 449,272 shares | US#2,183/3,116 Sec#214/265 |
| Trading Value | $10M | US#2,336/3,116 Sec#185/265 |
| Per Share | ||
| EPS | $4.94 | US#687/3,116 Sec#20/265 |
| BPS | $17.07 | US#1,402/3,116 Sec#41/265 |
Company Info
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.